Trials / Completed
CompletedNCT01016210
The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- The Baruch Padeh Medical Center, Poriya · Other Government
- Sex
- Female
- Age
- 25 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leuveris | IV |
| DRUG | Leuveris | All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day. |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2012-03-01
- Completion
- 2013-04-01
- First posted
- 2009-11-19
- Last updated
- 2014-01-17
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01016210. Inclusion in this directory is not an endorsement.